Q-Line Biotech Ltd
Q-Line Biotech Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
4 of 4 strong
The short version
Targeting revenue growth of approximately 30% to 35% in FY27 driven by increased utilization of manufacturing facilities and commercialization of new products (Page 6, 5). Q-Line Biotech targets revenue growth of approximately 30% to 35% for FY27, driven by increased utilization of manufacturing facilities, new product commercialization, export expansion, and disciplined cost management.
From Q-Line Biotech Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Targeting revenue growth of approximately 30% to 35% in FY27 driven by increased utilization of manufacturing facilities and commercialization of new products (Page 6, 5).
- Reagents revenue expected to grow by 30% to 35% in the current year, continuing as the primary growth driver due to recurring demand and strong margins (Page 7, 6; Page 5, 5).
- Installed base of instruments growing with plans to add 2,000+ instruments in the current year, supporting recurring reagent sales (Page 10, 9).
- Unit 4 manufacturing facility capacity expected to scale 3x to 4x current revenue in reagent and CDMO business by FY30 (Page 15, 14).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Q-Line Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major capex expected in the next 2-3 years; current CWIP (~INR 15 crore) mostly for a new plant planned to be used as warehouse initially.
- Additional capex possible if CDMO business for large equipment grows, requiring expanded space.
- Unit 4 manufacturing capacity allows 3-4x current revenue growth without extra capex, supporting reagent and CDMO expansion.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Q-Line Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Q-Line Biotech has an installed base of approximately 16,000 to 17,000 diagnostic instruments to date.
- The company plans to add around 2,000 new instruments in the current financial year.
- Installed base increased by 2,500 instruments in the last two years.
- Annual instrument placements average 1,200 to 1,300 units, with expected growth to over 2,000 units next year.
- Export orders are in early stages with revenues around INR1.2 crores last year; targeted 5x growth in FY27 (excluding CDMO).
2 more points management made on order book & pipeline
Continue your research
Others in Healthcare Equipment & Supplies this season
- OSEL Devices Ltd (Q4 FY26)
PAT growth was 45.7% in FY26; management is optimistic about sustaining or improving profitability and EPS in coming years. Key concall takeaways from OSEL…
- Vasa Denticity (Q4 FY26)
The company has a debt line of ₹15 crore available from financial partners. Key concall takeaways from Vasa Denticity Ltd's Q4 FY26 earnings call — and how it…
- QMS Medical (Q4 FY26)
INR 13 crores in FY26 to INR 18-20 crores in FY27. Key concall takeaways from QMS Medical's Q4 FY26 earnings call — and how it ranks against sector peers.
- Tarsons Products (Q4 FY26)
Margins may face pressure short-term due to raw material price volatility but should stabilize around current levels (gross margin not below 65%). Key concall…
Frequently Asked Questions
What were Q-Line Biotech Ltd Q4 FY26 results?
Targeting revenue growth of approximately 30% to 35% in FY27 driven by increased utilization of manufacturing facilities and commercialization of new products (Page 6, 5). Q-Line Biotech targets revenue growth of approximately 30% to 35% for FY27, driven by increased utilization of manufacturing facilities, new product commercialization, export expansion, and disciplined cost management.
What is Q-Line Biotech Ltd share price analysis?
Q-Line Biotech Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 28.8 with a market cap of ₹1,626 Cr. Investors should review the full earnings analysis for detailed insights.
Is Q-Line Biotech Ltd planning capital expenditure?
No major capex expected in the next 2-3 years; current CWIP (~INR 15 crore) mostly for a new plant planned to be used as warehouse initially.
Keep Q-Line Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.